Our Abpromise guarantee covers the use of ab17506 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA Use a concentration of 0.5 µg/ml. This concentration allows the detection of 0.2 - 0.4 ng/well of recombinant hIL6.
WB Use a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 26 kDa.
Neutralising Use a concentration of 0.2 - 0.4 µg/ml. To yield one half maximal inhibition (ND50) of the biological activity of hIL6 (1.0 ng/ml).


  • FunctionCytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoeitic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.
  • Involvement in diseaseGenetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.
    Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.
  • Sequence similaritiesBelongs to the IL-6 superfamily.
  • Post-translational
    N- and O-glycosylated.
  • Cellular localizationSecreted.
  • Information by UniProt
  • Database links
  • Alternative names
    • Interleukin BSF 2 antibody
    • B cell differentiation factor antibody
    • B cell stimulatory factor 2 antibody
    • B-cell stimulatory factor 2 antibody
    • BSF 2 antibody
    • BSF-2 antibody
    • BSF2 antibody
    • CDF antibody
    • CTL differentiation factor antibody
    • Hepatocyte stimulatory factor antibody
    • HGF antibody
    • HSF antibody
    • Hybridoma growth factor antibody
    • Hybridoma growth factor Interferon beta-2 antibody
    • IFN-beta-2 antibody
    • IFNB2 antibody
    • IL 6 antibody
    • IL-6 antibody
    • IL6 antibody
    • IL6_HUMAN antibody
    • Interferon beta 2 antibody
    • Interferon beta-2 antibody
    • Interleukin 6 antibody
    • Interleukin 6 (interferon beta 2) antibody
    • Interleukin BSF 2 antibody
    • Interleukin-6 antibody
    see all

References for Anti-IL6 antibody (ab17506)

This product has been referenced in:
  • Dickmann LJ  et al. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos 39:1415-22 (2011). Human . Read more (PubMed: 21555507) »

See 1 Publication for this product

Product Wall

The antibodies were not processed in such a way to induce fragmentation – they should still be dimers.